Press Release
Vision Marine Positions for Growth with Exclusive Nimbus Boats USA Distribution on Florida's West Coast
Exclusive Letter of Intent for West Coast distribution of Nimbus Boats USA Expands Nautical Ventures' lineup with premium Scandinavian‑designed models Strategic step to broaden Vision Marine's portfolio after acquiring Nautical Ventures Enhances choice and experience for boaters in Florida's top market Read More
Press Release
Zoned Properties Announces Profitable Q2 2025 Financial Results with Positive Cash Flow from Operations
Revenue for the Six Months Ended June 30, 2025 Increased 25% Income from Operations for the Six Months Ended June 30, 2025 Increased 202% Net Income for the Six Months Ended June 30, 2025 Increased 168% The Company currently holds 170,687 common shares in Treasury from its Repurchase Program Read More
Press Release
Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue
The combined net Q2 2025 revenue of approximately $3.0 million for prescription and non-prescription products, including license revenue, increased approximately 35% versus net Q1 2025 revenue of approximately $2.2 million and increased approximately 10% versus net Q2 2024 revenue of approximately $2.7 million Mytesi prescription volume increased approximately 6.5% in Q2 2025 over Q1 2025 and Mytesi prescription volume in Q2 2025 was equal to the volume in Q2 2024 As announced, initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required total parenteral nutrition in the first participating microvillus inclusion disease (MVID) patient by up to 27% and in the first participating short bowel syndrome (SBS-IF) patient by up to 12.5%; FDA meeting resulted in planned Jaguar regulatory pathway to complete supplemental NDA strategy for crofelemer for patients with metastatic breast cancer, a population meeting orphan definition in US Company strategy: Seek business development partnerships for license to develop and commercialize Jaguar's orphan indication products, resulting in non-dilutive funding for Jaguar REMINDER: Today Jaguar to host investor webcast at 8:30 a.m. Eastern regarding Q2 2025 financials and company updates; Click here to register Read More
Press Release
Interactive Strength Inc. (Nasdaq:TRNR) Reports Second Quarter 2025 Results; Increases 2025 Pro Forma Revenue Guidance to More Than $80M
Company Reports Quarterly Revenue of $1.2 Million; Net Loss and Loss per Diluted Share of $2.2 Million and $2.13 Quarterly Adjusted EBITDA Loss of $1.7 Million Reflects 40% YOY Improvement TRNR held 29.6 Million FET tokens as of June 30, 2025 and 67.4 Million FET tokens as of August 13, 2025, with a value in excess of $50 million, representing the largest publicly traded AI-focused Digital Asset Treasury Stockholders' Equity Was $16.3 Million at Quarter End 2025 Pro Forma Revenue Guidance Increased to more than $80 Million, driven by Sportstech's Stronger-Than-Expected Performance, and Fourth Quarter Profitability Guidance Reiterated Read More
Press Release
BK Technologies Announces Second Quarter 2025 Results
2Q25 Revenue growth to $21.2 million; Gross margin improves to 47.4% from 37.3% in 2Q24 2Q25 GAAP diluted EPS of $0.96 compared with $0.47 in 2Q24 2Q25 non-GAAP diluted adjusted EPS1of $1.30 compared with $0.55 in 2Q24 Raising full year 2025 GAAP EPS target to $3.15 per diluted share from $2.40 per diluted share Raising full year 2025 non-GAAP adjusted EPS1 target to $3.80 per diluted share from $2.80 per diluted share Announced $12.9 million in purchase orders from the USDA Forest Service subsequent to the quarter Read More
Press Release
CCL Industries Announces Record Results for 2025 Second Quarter
Second Quarter Highlights Per Class B share(3): $1.22 adjusted basic earnings up 8.0%; $1.21 basic earnings down 22.4%; 2024 included $0.44 revaluation gain in basic earnings Sales increased 4.8% on 2.0% organic growth, 1.0% acquisition growth and 1.8% positive currency translation Operating income(1) improved 6.1%, with a 16.6% operating margin(1) up 20 bps Returned $155.8 million to shareholders: $55.8 million in dividends and repurchased 1.3 million Class B shares for $100.0 million Six-Month Highlights Per Class B share(3): $2.40 adjusted basic earnings up 8.6%; $2.39 basic earnings down 9.5%; 2024 included $0.44 revaluation gain in basic earnings Sales increased 6.7% on 2.9% organic growth, 1.2% acquisition growth and 2.6% positive currency translation Operating income(1) improved 9.1%, with a 16.7% operating margin(1) up 40 bps Returned $312.1 million to shareholders: $112.1 million in dividends and repurchased 2.6 million Class B shares for $200.0 million Read More
Press Release
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
- Dermata announced additional positive data from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial- - Raised $8.8 million in gross proceeds from a private placement and warrant inducement financings during the first half of 2025 - Read More
Press Release
Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates
Initiates Critical Milestone, Launching Phase 3 Trial of PF614 to Advance Next-Generation Opioid Therapy Toward Regulatory Approval Receives $5.3 Million Installment from NIDA To Support Overdose Protection Program Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2 Read More
Press Release
Loop Industries' India Joint Venture Reaches Agreement to Acquire Strategic Site in Gujarat, India, for Infinite Loop Manufacturing Facility
Agreement reached to acquire site in the Gujarat state in India with strategic access to textile waste for feedstock, renewable clean energy, industrial infrastructure. Sufficient land on site for both initial 70,000 metric ton facility and further 100,000 metric ton capacity expansion. Total cost of the land is $10.5M which represents $5M reduction in the amount included in project cost estimate. Read More
Press Release
Ainos Reports Second Quarter 2025 Financial Results
1H 2025 Kicks Off AI Nose's Growing Commercial Momentum with First Senior Care Revenue and New Strategic Partnerships AI Nose 90-Day Roadmap to Power 2H 2025, with First Multi-Year $2.1M Order and Traction Across Robotics, Semiconductors, and Smart Manufacturing Read More
Press Release
Electrovaya Reports Q3 Fiscal Year 2025 Results
Revenue increased 67% y/y to $17.1M with Positive Adjusted EBITDA1 for Ninth Consecutive Quarter Adjusted EBITDA1 increased 387% y/y to $2.9M or 17% of revenue Net Profit for the quarter of $0.9M and EPS of $0.02 Reaffirms Fiscal 2025 Revenue Guidance Exceeding $60M, Driven by Strong Order Pipeline Read More
Press Release
